Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zafgen Inc (ZFGN)

Zafgen Inc (ZFGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,095
  • Shares Outstanding, K 37,470
  • Annual Sales, $ 0 K
  • Annual Income, $ -45,410 K
  • 60-Month Beta 0.27
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.73
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.81
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/14/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +312,287.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7400 +33.78%
on 05/01/20
1.2900 -23.26%
on 05/26/20
+0.2117 (+27.20%)
since 04/28/20
3-Month
0.6191 +59.91%
on 03/19/20
1.3200 -25.00%
on 03/04/20
-0.1500 (-13.16%)
since 02/28/20
52-Week
0.6191 +59.91%
on 03/19/20
2.7600 -64.13%
on 05/29/19
-1.6700 (-62.78%)
since 05/28/19

Most Recent Stories

More News
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics

- Shares of combined company to commence trading on Nasdaq Global Market under the symbol "LRMR" on May 29, 2020

ZFGN : 0.9900 (-14.66%)
LRMR : 10.62 (-3.45%)
Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results

Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement

ZFGN : 0.9900 (-14.66%)
Zafgen Inc Rises 7.62% on Heavy Volume: Watch For Potential Pullback

Zafgen Inc (NASDAQ:ZFGN) traded in a range yesterday that spanned from a low of $0.81 to a high of $0.87. Yesterday, the shares gained 7.6%, which took the trading range above the 3-day high of $0.73...

ZFGN : 0.9900 (-14.66%)
SmarTrend Watching for Potential Rebound in Shares of Zafgen Inc After 12.83% Loss

Zafgen Inc (NASDAQ:ZFGN) traded in a range yesterday that spanned from a low of $0.62 to a high of $0.73. Yesterday, the shares fell 12.8%, which took the trading range below the 3-day low of $0.78 on...

ZFGN : 0.9900 (-14.66%)
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases

ZFGN : 0.9900 (-14.66%)
Look for Shares of Zafgen Inc to Potentially Pullback after Yesterday's 5.23% Rise

Zafgen Inc (NASDAQ:ZFGN) traded in a range yesterday that spanned from a low of $0.80 to a high of $0.82. Yesterday, the shares gained 5.2%, which took the trading range above the 3-day high of $0.81...

ZFGN : 0.9900 (-14.66%)
Zafgen Reports Third Quarter 2019 Financial Results

Evaluation of strategic alternatives ongoing

ZFGN : 0.9900 (-14.66%)
Zafgen to Explore Strategic Alternatives

Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic...

ZFGN : 0.9900 (-14.66%)
Zafgen Reports Second Quarter 2019 Operating and Financial Results

Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins

ZFGN : 0.9900 (-14.66%)
Zafgen to Present at the Wedbush PacGrow Healthcare Conference

Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic...

ZFGN : 0.9900 (-14.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ZFGN with:

Business Summary

Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity...

See More

Key Turning Points

2nd Resistance Point 1.3500
1st Resistance Point 1.1700
Last Price 0.9900
1st Support Level 0.8800
2nd Support Level 0.7700

See More

52-Week High 2.7600
Fibonacci 61.8% 1.9422
Fibonacci 50% 1.6895
Fibonacci 38.2% 1.4369
Last Price 0.9900
52-Week Low 0.6191

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar